REG - N4 Pharma PLC - Oral Delivery Update

N4 PharmaAnnouncement

18/12/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231218:nRSR0368Xa&default-theme=true

RNS Number : 0368X  N4 Pharma PLC  18 December 2023

 

18 December 2023

N4 Pharma plc

 ("N4 Pharma" or the "Company")

 

Oral Delivery Update

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing
Nuvec®, a novel delivery system for cancer treatments and vaccines, is
pleased to provide a positive update on its ongoing oral delivery research
work.

 

The Company through its research program with the University of Queensland is
evaluating the potential of Nuvec® to act as an oral delivery system for
oligonucleotides including DNA and RNA.

 

Experiments have now confirmed, in vivo, the successful oral administration of
Nuvec® loaded with a DNA plasmid for ovalbumin. The Nuvec® was administered
by enteric coated capsule and the contents, having been released in the
intestinal lumen, were taken up by intestinal cells, with successful
transfection and release of the newly synthesized ovalbumin.

 

Specifically, the first experiment was a repeat of a study conducted earlier
this year whereby an enterically coated capsule containing Nuvec® loaded with
a DNA plasmid for ovalbumin was administered and protein expression was
observed after 3 days. In this recent experiment, an additional second capsule
was administered on day 3 which resulted in a much higher peak level of
expression on days 4-7.

 

Nigel Theobald, Chief Executive Officer of the Company, commented:

 

"This continued success shows that Nuvec® has the potential to be
successfully used as an oral delivery system with many potential applications
such as a vaccine, a product for Irritable Bowel Disease or to treat colonic
cancer among many possible examples. Given the complexities involved in oral
delivery this early success with Nuvec® represents a potentially massive
opportunity and point of difference for Nuvec® and its use as delivery system
to target multiple diseases.

 

"With this new data we are in the process of scoping out the next phase of
work to accumulate sufficient data to enable us to focus on a specific oral
application and further news on this will be announced in the new year and we
expect to make advancing Nuvec's® use as an oral delivery technology a key
priority for 2024. In the meantime, the University of Queensland will continue
its work exploring the use of Nuvec® as an oral delivery system for vaccines
as part of our Australian Research Council funded grant with them."

 

For more information please contact:

 

 N4 Pharma plc

 Nigel Theobald, CEO                                          Via N4 Pharma Investor Hub

 Luke Cairns, Executive Director

 Engage with us directly at N4 Pharma Investor Hub            Sign up at investors.n4pharma.com (https://investors.n4pharma.com/)
 SP Angel Corporate Finance LLP                               Tel: +44(0)20 3470 0470

 Nominated Adviser and Joint Broker

 Matthew Johnson/Kasia Brzozowska (Corporate Finance)

 Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
 Turner Pope Investments (TPI) Limited                        Tel: +44(0)20 3657 0050

 Joint Broker

 Andy Thacker

 James Pope
 IFC Advisory Ltd                                             Tel: +44(0)20 3934 6630

 Financial PR

 Graham Herring

 Zach Cohen

 

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery
system for oncology, gene therapy and vaccines using its unique silica
nanoparticle delivery system called Nuvec®.

 

N4 Pharma's business model is to partner with companies developing novel
antigens in these fields to use Nuvec® as the delivery vehicle for these
antigens. As these products progress through pre‐clinical and clinical
programs, N4 Pharma will seek to receive upfront payments, milestone payments
and ultimately royalty payments once products reach the market.

 

For further information on the Company visit www.n4pharma.com
(http://www.n4pharma.com) or sign up at investors.n4pharma.com
(https://investors.n4pharma.com/) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFFLFIIEDSESE